Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 67

recruiting
3 973
countries
28
conditions
2 104

836 trials match your criteria

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Dermatomyositis

Not recruiting

Study on the Effects of GLPG3667 for Adults with Dermatomyositis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Tourette's disorder

Not recruiting

Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette's Disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years
  • Substances:Ecopipam Hydrochloride
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.